Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy

Blood

Volumn 89, Issue 4, 1997, Pages 1254-1259

  Le, MaiThao ^a   Okuyama, Torayuki ^a   Cai, Shi Rong ^a   Kennedy, Susan C ^a   Bowling, William M ^a   Flye, M Wayne ^a   Ponder, Katherine Parker ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Box 8125 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; COMPLEMENTARY DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING FACTOR 10 DEFICIENCY; CONTROLLED STUDY; GENE THERAPY; HEMOPHILIA; IMMUNOPRECIPITATION; LIVER REGENERATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; RETROVIRUS;

EID: 0031055741     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.4.1254     Document Type: Article

References (29)

1. Roberts HR, Huffman R: Hemophilia and related conditions-inherited deficiencies of prothrombin (factor II), factor V, and factors VII to XII, in Beutler E, Lichtman MA, Coller BS, Kipps TJ (eds): Hematology. New York, NY, McGraw Hill, 1995, p 1413
2. Brownlee GG: Prospects for gene therapy for haemophilia A and B. Br Med Bull 51:91, 1995
3. Thompson AR: Progress towards gene therapy for the hemophilias. Thromb Hemost 74:45, 1995
4. Lozier J, Brinkhous KM: Gene therapy and the hemophilias. JAMA 271:47, 1994
5. Ponder KP: Gene delivery for systemic expression, in March K (ed): Gene Therapy for Cardiovascular Disease. New York, NY, McGraw-Hill (in press)
6. Connelly S, Smith TAG, Dhir G, Gardner JM, Mehaffey MG, Zaret KS, McClelland A, Kaleko M: In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum Gene Ther 6:185, 1995
7. Connelly S, Gardner JM, McClelland A, Kaleko M: High-level tissue-specific expression of functional human factor VIII in mice. Hum Gene Ther 7:183, 1996
8. Dai Y, Schwartz EM, Gu D, Zhang W-W, Sarvetnick N, Verma IM: Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 92:1401, 1995
9. Kay MA, Landen CN, Rothenberg SR, Taylor LA, Leland F, Wiehle S, Fang B, Bellinger D, Finegold M, Thompson AR, Read M, Brinkhous KM, Woo SLC: In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 91:2353, 1994
10. Smith TAG, Mehaffey MG, Kayda DB, Saunders JM, Yei S, Trapneck BC, McClelland A, Kaleko M: Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet 5:397, 1993
11. Walter J, You Q, Hagstrom JN, Sands M, High KA: Successful expression of human factor IX following repeat administration of an adenoviral vector in mice. Proc Natl Acad Sci USA 93:3056, 1996
12. Perales JC, Ferkol T, Beegen H, Ratnoft OD, Hanson RW: Gene transfer in vivo: Sustained expression of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci USA 91:4086, 1994
13. Kay MA, Rothenberg S, Bellinger DA, Leland F, Tomin C, Reed MS, Brinkhouse KM, Woo SLC: In vivo gene therapy of hemophilia B: Sustained partial correction in factor IX deficient dogs. Science 266:117, 1993
14. Dai Y, Roman M, Naviaux RK, Verma IM: Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci USA 89:10892, 1992
15. Yao S-N, Smith KJ, Kurachi K: Primary myoblast-mediated gene transfer: Persistent expression of human factor IX in mice. Gene Ther 1:99, 1994
16. Rettinger SD, Kennedy S, Wu X, Hafenrichter D, Flye MW, Ponder KP: Liver-directed gene therapy: Quantitative evaluation of promoter elements using in vivo retroviral transduction. Proc Natl Acad Sci USA 91:1460, 1994
17. Hafenrichter DG, Rettinger SD, Kennedy S, Wu X, Flye MW, Ponder KP: Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes. Blood 84:3394, 1994
18. 1-antitrypsin in vivo. Hum Gene Ther 5:637, 1996
19. Rettinger SD, Ponder KP, Saylors RL, Kennedy SC, Hafenrichter DG, Flye MW: In vivo hepatocyte transduction with retrovirus during in-flow occlusion. J Surg Res 52:418, 1993
20. Leytus SP, Chung DW, Kisiel W, Kurachi K, Davie EW: Characterization of a cDNA for human factor X. Proc Natl Acad Sci USA 81:3699, 1984
21. Markowitz D, Goff S, Bank A: Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167:400, 1988
22. Jainchill JL, Aaronson SA, Todoro GJ: Murine sarcoma and leukemia viruses: Assay using clonal lines of contact inhibited mouse cells. J Virol 4:549, 1969
23. Darlington G: Liver cell lines. Methods Enzymol 151:1938. 1987
24. Kotani H, Newton PB, Zhang S, Chiang YL, Otto E, Weaver L, Blaese RM, Anderson WF, McGarrity GJ: Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther 5:19, 1994
25. Harlow E, Lane D: Immunoassays, in Harlow E, Lane D (eds): Antibodies: A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1988, p 553
26. Hung H-L, High KA: Liver-enriched transcription factor HNF-4 and ubiquitous factor NF-Y are critical for expression of blood coagulation factor X. J Biol Chem 271:2323, 1996
27. Fang B, Eisensmith RC, Want H, Kay MA, Cross RE, Landen CN, Gordon G, Bellinger DA, Read MS, Hu PC, Brinkhous KM, Woo SLC: Gene therapy for hemophilia B: Host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 6:1039, 1995
28. Bowling WM, Kennedy SC, Cai SR, Duncan JR, Gao C, Flye MW, Ponder KP: Portal branch occlusion safely facilitates in vivo retroviral vector transduction of rat liver. Hum Gene Ther 7:2113, 1996
29. Lieber A, Vrancken Peeters MJ, Gown A, Perkins J, May MA: A modified urokinase activator induces liver regeneration without bleeding. Hum Gene Ther 6:1029, 1995